TY - JOUR
T1 - Japanese national survey on declined liver allografts from brain-dead donors
T2 - High decline rate but promising outcomes in allografts with moderate steatosis
AU - Takemura, Yusuke
AU - Shinoda, Masahiro
AU - Hasegawa, Yasushi
AU - Yamada, Yohei
AU - Obara, Hideaki
AU - Kitago, Minoru
AU - Kasahara, Mureo
AU - Umeshita, Koji
AU - Eguchi, Susumu
AU - Kitagawa, Yuko
AU - Ohdan, Hideki
AU - Egawa, Hiroto
N1 - Funding Information:
Author Yuko Kitagawa is Editor in Chief of Annals of Gastroenterological Surgery. Author Hideki Ohdan and Susumu Eguchi are current Editors of Annals of Gastroenterological Surgery. Author Yuko Kitagawa received lecture fees from Asahi Kasei Pharma Co., AstraZeneca K.K., Ethicon Inc., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., Olympus Corporation, Nippon Covidien Inc., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol‐Myers Squibb K.K., MSD K.K., Smith & Nephew K.K., Kaken Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., Miyairisan Pharmaceutical Co., Ltd., Toray Industries, Inc., Daiichi Sankyo Company, Ltd., Chugai Foundation for Innovative Drug Discovery Science, and Nippon Kayaku Co., Ltd. Author Yuko Kitagawa was supported by grants from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd., Asahi Kasei Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Tsumura & Co., Kaken Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., EA Pharma Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Factory Inc., Medicon Inc., Kyouwa Hakkou Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and Nippon Covidien Inc. Author Yuko Kitagawa held an endowed chair provided by Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd., outside the submitted work.
Publisher Copyright:
© 2023 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery.
PY - 2023/7
Y1 - 2023/7
N2 - Aim: Liver allografts from brain-dead donors, which were declined and were eventually not transplanted due to accompanying marginal factors, have never been surveyed in Japan. We surveyed the declined allografts and discussed the graft potential focusing on various marginal factors. Methods: We collected data on brain-dead donors between 1999 and 2019 from the Japan Organ Transplant Network. We divided their liver allografts into declined (nontransplanted) and transplanted ones, and then characterized declined ones focusing on their timepoints of decline and accompanying marginal factors. For each marginal factor, we calculated the decline rate from the number of declined and transplanted allografts, and assessed the 1-year graft survival rate from transplanted allografts. Results: A total of 571 liver allografts were divided into 84 (14.7%) declined and 487 (85.3%) transplanted ones. In the declined allografts, a majority was declined after laparotomy (n = 55, 65.5%), most of which had steatosis and/or fibrosis (n = 52). Out of the moderate steatotic (without F ≥ 2 fibrosis) allografts (n = 33), 21 were declined and 12 were transplanted, leading to a 63.6% decline rate. The latter 12 achieved a 92.9% 1-year graft survival rate after transplantation. Comparison of donor background showed no significant difference between the declined and transplanted allografts. Conclusion: Pathological abnormalities of steatosis/fibrosis seem to be the most common donor factor leading to graft decline in Japan. Allografts with moderate steatosis were highly declined; however, transplanted ones achieved promising outcomes. This national survey highlights the potential utility of liver allografts with moderate steatosis.
AB - Aim: Liver allografts from brain-dead donors, which were declined and were eventually not transplanted due to accompanying marginal factors, have never been surveyed in Japan. We surveyed the declined allografts and discussed the graft potential focusing on various marginal factors. Methods: We collected data on brain-dead donors between 1999 and 2019 from the Japan Organ Transplant Network. We divided their liver allografts into declined (nontransplanted) and transplanted ones, and then characterized declined ones focusing on their timepoints of decline and accompanying marginal factors. For each marginal factor, we calculated the decline rate from the number of declined and transplanted allografts, and assessed the 1-year graft survival rate from transplanted allografts. Results: A total of 571 liver allografts were divided into 84 (14.7%) declined and 487 (85.3%) transplanted ones. In the declined allografts, a majority was declined after laparotomy (n = 55, 65.5%), most of which had steatosis and/or fibrosis (n = 52). Out of the moderate steatotic (without F ≥ 2 fibrosis) allografts (n = 33), 21 were declined and 12 were transplanted, leading to a 63.6% decline rate. The latter 12 achieved a 92.9% 1-year graft survival rate after transplantation. Comparison of donor background showed no significant difference between the declined and transplanted allografts. Conclusion: Pathological abnormalities of steatosis/fibrosis seem to be the most common donor factor leading to graft decline in Japan. Allografts with moderate steatosis were highly declined; however, transplanted ones achieved promising outcomes. This national survey highlights the potential utility of liver allografts with moderate steatosis.
KW - deceased-donor liver transplantation
KW - donor selection
KW - fibrosis
KW - graft survival
KW - steatosis
UR - http://www.scopus.com/inward/record.url?scp=85147563219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147563219&partnerID=8YFLogxK
U2 - 10.1002/ags3.12661
DO - 10.1002/ags3.12661
M3 - Article
AN - SCOPUS:85147563219
SN - 2475-0328
VL - 7
SP - 654
EP - 665
JO - Annals of Gastroenterological Surgery
JF - Annals of Gastroenterological Surgery
IS - 4
ER -